OncoSec Medical Incorporated (NASDAQ:ONCS) said on Tuesday that it plans to offer for sale a combination of shares of its common stock and warrants in an underwritten public offering.

Subject to market conditions, there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

AGP/Alliance Global Partners is acting as sole book-running manager for the offering.

The late-stage cancer biotechnology company develops intratumoral gene-delivery immunotherapies, including its lead immunotherapy platform TAVO (tavokinogene telseplasmid), which enables the intratumoral delivery of DNA-based interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions.